1. Introduction {#s0005}
===============

The United States is suffering its most serious drug-related public health crisis in a generation ([@b0675]). Prescription opioid-related mortality rates increased by nearly 400% between 2000 and 2014; this period has also seen substantial increases in prevalence of opioid use disorder and rates of opioid-related hospitalizations ([@b0310], [@b0540], [@b0610], [@b1035], [@b1145]). Heroin overdose deaths have more than quadrupled since 2010, and of the more than 47,000 opioid overdose deaths in 2017, nearly one-third involved heroin and over half involved synthetic opioids (e.g., fentanyl) ([@b1095]). Multiple factors have contributed to the rise in opioid-related morbidity and mortality, and reducing the social and public health costs of opioid harms requires a multi-pronged approach ([@b0265], [@b0260], [@b0675], [@b0725], [@b1240]). To this end, the Department of Health and Human Services (HHS)[1](#fn1){ref-type="fn"} has identified five key strategies to combat the opioid crisis: 1) advancing better pain management practices; 2) improving addiction prevention, treatment, and recovery services; 3) promoting use of overdose reversing drugs; 4) strengthening data for better public health surveillance; and 5) supporting better research across the first four strategies ([@b0940], [@b1180]).

Advancing these strategies often relies on analyses of non-clinical secondary data, yet researchers may be unaware of many available existing data sources ([@b1115]). Organized by the first four HHS strategies ([@b0285]), this review seeks to address this issue through identifying commonly used secondary data sources, the types of outcomes they are used to examine, their strengths and limitations, and promising data-linkage opportunities to support better research. Using a mixed-methods approach combining qualitative interviews with a scoping study to identify commonly used secondary data sources and data linkage strategies that could support better research, this article complements existing reviews of available data sources and metrics for studying prescription opioid use ([@b0275], [@b1085], [@b1100]).

2. Methods {#s0010}
==========

We employed a multi-phase approach to synthesize information from the literature, opioid research experts, and policymakers as part this HHS-funded study. We first conducted a scoping study, consistent with established methods ([@b0030], [@b0730]), to identify commonly used data sources and data linking strategies in existing opioid research, focused on the United States context. The scoping study was complemented by semi-structured interviews with policymakers and opioid services and policy researchers to identify existing data source strengths and limitations, innovative uses of data and data linkages, and opportunities to use such data to address high-priority research questions. The RAND Institutional Review Board determined the project exempt.

To identify data sources, we searched for literature published between 2005 and 2017 through databases including PubMed, OVID, CINAHL, and PsycINFO using terms such as "opioid, "buprenorphine," "methadone," and "naloxone," as well as terms specific to opioid policy interventions such as "prescription monitoring program," "pill mill," and "Good Samaritan." We used similar terms to conduct an internet search for relevant non-peer reviewed reports or presentations, and we reviewed additional articles and reports cited in key documents. We extracted information related to each document's content, including research objective, outcome measures, and key variables and identified specific data sources, geographic coverage, time period, and data linkages in documents using empirical data. Data linkages were defined as any analysis combining data from multiple sources to study the same individual, policy, or geographic area.

The scoping study was complemented by 30-minute semi-structured interviews with sixteen opioid policy researchers and federal program officials conducted in August and September of 2017 (see Appendix for interview guide). Interviewees were selected by HHS officials to obtain a diverse set of perspectives. Discussions were tailored to the interviewees' expertise and designed to gather insights on existing dataset strengths, limitations, and promising opportunities for dataset linkage. Research team members used detailed interview notes to identify common themes related to current dataset uses as well as potential opportunities to address key policymaker questions. In the twelve months subsequent to the interviews, the scoping study was updated to capture more recent literature published through December 2018, with particular attention to research questions, datasets, or data linkages previously identified as gaps by interviewees.

3. Review {#s0015}
=========

The scoping study identified 446 articles and reports; 306 (68.6%) involved discussion or analyses of existing datasets; the remainder involved primary data collection or did not use empirical data (e.g., editorials, reviews). Existing datasets were wide-ranging but categorized generally as national surveys, electronic health records (EHR) and claims, mortality records, prescription drug monitoring program (PDMP) data, contextual or policy data, and other national, state, or local data sources (e.g., national poison control center data, state arrest records). Interviewees discussed barriers or challenges in accessing datasets, their experiences linking datasets, and how datasets could be used to answer key research questions.

In [3.1](#s0020){ref-type="sec"}, [3.2](#s0030){ref-type="sec"}, [3.3](#s0040){ref-type="sec"}, [3.4](#s0050){ref-type="sec"}, we provide further detail on commonly used data sources, organized by HHS strategy. In the tables, we provide information on commonly used data sources and specific data elements, strengths and limitations for the different types of data, as well as data linking strategies for each HHS area. We subsequently highlight common topics arising during semi-structured interviews.

3.1. Advancing better pain management practices {#s0020}
-----------------------------------------------

An estimated 20% of non-cancer outpatients with pain receive opioid analgesics ([@b0320]), chronic use of which increases risk of opioid use disorder ([@b0100], [@b0245]) and opioid-related harms ([@b0250], [@b1140]). Researchers have commonly sought to identify the relationship between prescribing policy interventions, opioid analgesic prescribing and distribution, opioid-related overdose, and state- or community-level contextual factors ([Table 1](#t0005){ref-type="table"}). In this section, we review measures, data sources, and linkages commonly used in this research, and we summarize common themes in this area from the interviews.Table 1Secondary Data Sources to Support Research toward Advancing Better Pain Management Practices.**Data Elements (by Topic)SourcesStrengths and LimitationsPolicy dataPrescribing interventions**•PDMPs•Pain clinic laws•Education requirements•Prescribing limits•PDAPS•NAMSDL[\*](#tblfn1){ref-type="table-fn"}•CDC Public Health Law Program[\*](#tblfn1){ref-type="table-fn"}Strengths:+Can be linked with outcome data to examine state policy impactLimitations:-Some data not provided in analyzable format-May not fully capture heterogeneity in state laws-Some policy information not available historically for longitudinal analysis**EHR and claims dataOpioid prescribing and distribution**•Opioid analgesic prescribing•Prescription characteristics (opioid type, dose, days\' supply, MED)•Other prescriptions•Payment**Opioid-related overdose**•Diagnostic codes for nonfatal overdose**Detection of opioid misuse & morbidity**•Inpatient stays and ED visits•Diagnoses and procedures•Costs**Commercial claims**•Healthcore•Marketscan•IQVIAStrengths:+Multi-payer and may include cash paymentsLimitations:-Not set up to track people long-term given insurance coverage transitions-Limited information on patient diagnoses or healthcare utilization-Difficult to link to outcomes (e.g., mortality)**Federal claims**•Medicare data•National or state Medicaid datasetsStrengths:+Can link hospital and pharmacy claims+Can look at Rx histories of patients who go to a hospital/ED for overdoseLimitations:-Provides information on one population (Medicare or Medicaid enrollees)-Not set up to track people long-term given insurance coverage transitions-Cannot measure opioid mortality as provides date but not cause of death**VHA data warehouse**Strengths:+VHA data warehouse enables linkages across datasets+Has been linked to NDILimitations:-Limited accessibility**HCUP** (national and state inpatient and emergency department databases)Strengths:+Large collection of longitudinal data, nation-wide and state-level; free portal access to opioid-related data+State data is mapped to a standardized formatLimitations:-Not all states participate in the databases-Costs to obtain full datasets**Prescription drug monitoring dataOpioid prescribing and distribution**•Prescription name/type•Prescription dose, days' supply, MED•Prescriber•Payment•State PDMPs•PBSS•ARCOSStrengths:+Comprehensive data on distribution (ARCOS) or prescribing (PDMP)+PDMPs used to develop measures for patient/prescriber risk behaviorsLimitations:-Access barriers-ARCOS not available in computable formats (i.e., in PDF form)-State capacity issues may limit ability to link PDMP data with other datasets-PDMP systems may lack unique IDs or have ID entry errors, creating issues in identifying individual-level matches**Mortality dataOpioid-related overdose**•Cause of death•Drugs involved in death•Demographics•NDI•NVSS MCOD•CDC WONDER[\*](#tblfn1){ref-type="table-fn"}•State vital recordsStrengths:+National data with information on opioid overdose mortality+CDC WONDER is readily downloadable and publicly availableLimitations:-Lags in data availability-Variation in quality of reporting detail on drug involvement**Contextual dataContextual factors▪** Unemployment rate**▪** Physician density**▪** Demographics•BEA[\*](#tblfn1){ref-type="table-fn"}; CPS[\*](#tblfn1){ref-type="table-fn"}•BLS[\*](#tblfn1){ref-type="table-fn"}; ACS[\*](#tblfn1){ref-type="table-fn"}•AHRF[\*](#tblfn1){ref-type="table-fn"}•CMS[\*](#tblfn1){ref-type="table-fn"}Strengths:+Allows analyses to control for state or county factors related to opioid analgesic use or opioid analgesic prescribingLimitations:-Lags in data availability[^1]

The most common studies of opioid prescribing interventions examine the impact of PDMPs on opioid analgesic prescribing and opioid-related overdose. Data regarding PDMP policies ([@b0325], [@b1050]) commonly comes from the National Alliance for Model State Drug Laws (NAMSDL) or Prescription Drug Abuse Policy System (PDAPS) ([@b0035], [@b0040], [@b0135], [@b0235], [@b0355], [@b0475], [@b0495], [@b0740], [@b0745], [@b0840], [@b0890], [@b0905], [@b0910], [@b0965], [@b1010], [@b1050], [@b1255], [@b1300]), with additional information about PDMP components obtained from Temple University's Policy Surveillance Program or Brandeis' PDMP Training Technical Assistance Center ([@b0135], [@b0325], [@b0890], [@b0905], [@b0965], [@b1250], [@b1255]). Case studies of opioid prescribing guidelines or directives generally rely on data from site-specific implementation ([@b0140], [@b0240], [@b0350], [@b0545], [@b0590], [@b1215], [@b1260]). Studies of other state prescribing regulations such as ID laws, continuing education requirements, doctor shopping laws, and physician exam requirements use CDC Public Health Law Program or original review of legal documents ([@b0045], [@b0325], [@b0335], [@b0700], [@b0930]). Finally, studies evaluating the effects of Florida's pill mill laws use information on the policy's implementation ([@b0235], [@b0650], [@b1050]).

Research examining opioid analgesic prescription characteristics, prescribing behavior, and dispensing patterns ([Table 1](#t0005){ref-type="table"}) commonly uses prescription information from commercial ([@b0205], [@b0210], [@b0215], [@b0235], [@b0375], [@b0500], [@b0715], [@b0750], [@b0960], [@b1050], [@b1090]) and Medicaid pharmacy claims ([@b0115], [@b0280], [@b0440], [@b0550], [@b0660], [@b0750], [@b0770], [@b0970], [@b1020], [@b1170], [@b1255], [@b1295]), Medicare Part D Prescription Drug Event data ([@b0135], [@b0455], [@b0555], [@b0700], [@b0840], [@b1280], [@b1300]), Veterans Health Administration (VHA) data ([@b0045], [@b0090], [@b0390], [@b0825], [@b0880], [@b0895], [@b1310]), and PDMP data ([@b0035], [@b0075], [@b0355], [@b0360], [@b0375], [@b0475], [@b0510], [@b0535], [@b0645], [@b0695], [@b0820], [@b0965], [@b1010], [@b1020]). PDMP studies usually entail single-state analyses, although the Prescription Behavior Surveillance System (PBSS), which compiles PDMP data from multiple states ([@b0915]), has allowed for multi-state comparisons of opioid misuse indicators. Several studies have examined state-level opioid analgesic distribution using the Automation of Reports and Consolidated Orders System (ARCOS) ([@b0015], [@b0120], [@b0910], [@b0990]).

To examine the relationship between opioid analgesic use and overdose, studies use person-level mortality records from the National Death Index (NDI) ([@b0095], [@b0090], [@b0895]) or state death certificate data ([@b0315], [@b0385], [@b0440], [@b0510], [@b0535], [@b0560], [@b0820], [@b0970]) and opioid-related toxicity or overdose event measures from Medicare ([@b0135], [@b0700]), commercial claims ([@b0115], [@b0715], [@b1170]), Medicaid ([@b0280], [@b1295]), and VHA databases ([@b0825], [@b1310]). Other research examines aggregate state- or county-level rates of fatal opioid overdose using state death certificate data ([@b0650]), the National Vital Statistics System Multiple Cause of Death (NVSS MCOD) microdata ([@b0015], [@b0375], [@b0740]), and CDC WONDER ([@b0290], [@b0485], [@b0890], [@b0905], [@b1000]).

To evaluate contextual factors related to opioid prescribing or opioid-related harms, studies commonly include state- or county-level measures of the unemployment rate and income per capita from the Bureau of Economic Analysis (BEA) ([@b0325]), Bureau of Labor Statistics (BLS) ([@b0905]), or American Community Survey (ACS) ([@b0500], [@b1090], [@b1300]); information on physician density and demographics from the Area Health Resource Files (AHRF) ([@b0325], [@b0500]); and rates of health insurance coverage from the Current Population Survey (CPS) or Centers for Medicare & Medicaid Services (CMS) ([@b0500], [@b1255], [@b1300]).

To examine how policies or community factors influence pain management practices, studies link state policy data and state- or county-level contextual factors to data on opioid prescribing ([@b0120], [@b0135], [@b0530], [@b0700], [@b0840], [@b1255], [@b1300]) or overdose mortality records ([@b0375], [@b0740], [@b0890], [@b0905]). Research examining potentially inappropriate prescribing generally links opioid prescription data with opioid overdose data at the person level. These include studies linking PDMP data with Medicaid claims ([@b0550], [@b0660]), hospital discharges ([@b0035], [@b0360]), death certificates or toxicology reports ([@b0010], [@b0360], [@b0510], [@b0820]), or data capturing state medical board actions ([@b0695]); analyses of multiple linked VHA databases ([@b0090], [@b0455], [@b1260]); and research linking Medicaid claims with state vital records, hospital discharge data, or the NDI ([@b0440], [@b0790], [@b0865], [@b0970]).

### 3.1.1. Common interview themes {#s0025}

The insufficient understanding of factors influencing opioid analgesic use and subsequent outcomes was a common theme, with interviewees noting a paucity of empirical research examining how changes in opioid prescribing guidelines, pain reimbursement policies, or clinician education protocols influence treatment of pain and subsequent risk for opioid misuse, addiction, and overdose. While recent studies have examined the impact of opioid prescribing guidelines within a single state ([@b0470], [@b1150], [@b1245]), the absence of systematically collected information on how guidelines are being implemented across states and over time complicates identification of the policy features that are effective. Interviewees also stressed the need for additional research examining longer-term effectiveness of opioid and non-opioid analgesic interventions for chronic pain given questions about the comparative effectiveness of opioid analgesics in managing some types of chronic pain ([@b0690], [@b0685]).

Additional common themes were the need for analyses of provider- or hospital-level opioid prescribing patterns to identify factors underlying provider- or practice-level variation in risky or inappropriate prescribing, and the need for longitudinal patient-level analyses with sufficient temporal coverage to examine the pathways and sequences of events associated with adverse outcomes following opioid analgesic prescribing. Interviewees also frequently observed that all-payer claims databases, such as that developed by Massachusetts ([@b0795]), may facilitate important longitudinal analyses that unlike Medicaid and commercial claims can track individuals as they transition across different types of insurance or across plans within a given insurance type.

3.2. Improving addiction prevention, treatment, and recovery services {#s0030}
---------------------------------------------------------------------

Despite considerable improvement in the availability of medication-assisted treatment ([@b1210]) substantial gaps between opioid use disorder treatment need and capacity persist ([@b0415], [@b0365], [@b0520], [@b0610], [@b0830], [@b1060]). In this section, we provide information about measures, data sources, and data linkages commonly used to study prevalence of opioid misuse or use disorders, treatment demand and utilization, supply and capacity of treatment, treatment policies, and contextual factors associated with treatment need and access ([Table 2](#t0010){ref-type="table"}), and we summarize common themes in this area from the interviews.Table 2Secondary Data Sources to Support Research on Improving Prevention, Treatment, and Recovery Services.**Data elements (by Topic)SourcesStrengths and limitationsEHR and claims dataOpioid misuse or use disorders**•Opioid use disorder diagnosis•Opioid-related inpatient stays and ED visits**Treatment demand & utilization**•Buprenorphine prescriptions•Payment•Monthly prescriber patient census**Individual-level risk factors**•Other Rx use or healthcare utilization•Socio-demographics; comorbidities**Commercial claims**•IQVIA•Marketscan•Symphony HealthStrengths:+Prescription data can capture the population treated with buprenorphineLimitations:-Limited information on patient diagnoses or other healthcare utilization-Requires triangulating with other sources to fully assess treatment need-Issues in tracking individuals over time**National or state Medicaid datasets**Strengths:+Can link hospital and pharmacy claims+Single-state analyses have linked to death dataLimitations:-Only provides information on Medicaid enrollees-Misses those receiving other publicly funded substance abuse treatment**VHA data warehouse**Strengths:+Facilitates linkage to treatment facility-level variables+Has been linked to NDILimitations:-Limited accessibility and specific population**HCUP** (national and state inpatient and emergency department databases)Strengths:+Large collection of longitudinal data, nation-wide and state-level; free portal access to opioid-related data+State data is mapped to a standardized formatLimitations:-Not all states participate in the databases-Costs to obtain full datasets**National surveysOpioid misuse or use disorders**•Nonmedical use of opioids•Opioid use disorder symptoms**Treatment demand & utilization**•Opioid use disorder treatment•Source of payment**Individual-level risk factors**•Mental health, substance use•Socio-demographics**Household surveys**•NSDUH[\*](#tblfn2){ref-type="table-fn"}•NESARCStrengths:+National data with rich information on substance use & mental health+NSDUH 2015 redesign asks about any pain reliever use (not only misuse)Limitations:-Does not ask about medications used for treatment or treatment retention-Screens for use disorder symptoms, but does not ask about formal diagnosis-Sample may miss high-risk populations (e.g., homeless, arrestees)-State identifiers restricted**Treatment demand & utilization**•\# treatment admissions•\# patients receiving methadone in OTPs (N-SSATS)•Referral source**Treatment supply & capacity** (N-SSATS only)•Treatment facility characteristics•Estimated operating capacity**Treatment facility surveys**•TEDS[\*](#tblfn2){ref-type="table-fn"}•N-SSATS[\*](#tblfn2){ref-type="table-fn"}Strengths:+National data on admissions to treatment & public-sector specialty care+TEDS has patient demographic data+Up to 3 drugs of abuse listed (differentiate heroin & opioid analgesics)+N-SSATS includes both public and private facilitiesLimitations:-TEDS only includes agonist treatments; cannot differentiate MAT types-Limited information on payment-Quality control issues with TEDS, as states may not consistently report on similar patients or have consistent procedures to assess data quality-TEDS data do not include private for-profit treatment facilities**Mortality dataOpioid-related overdose**•Cause of death•Drugs involved in death•Demographics•NDI•NVSS MCOD•CDC WONDER[\*](#tblfn2){ref-type="table-fn"}•State vital recordsStrengths:+National data with information on opioid overdose mortality+CDC WONDER is readily downloadable and publicly availableLimitations:-Lags in data availability-Variation in quality of reporting detail on drug involvement**Other national data sourcesTreatment supply & capacity**•Waivered physicians•Patient caps•Physician address, ZIP**Provider censuses**•SAMHSA database[\*](#tblfn2){ref-type="table-fn"}•DEA ACSAStrengths:+Measures supply/capacity of waivered physicians at geographic detail+Can link to AMA Physician MasterfileLimitations:-Costs to obtain DEA ACSA-SAMHSA publicly available data captures around 55% of physicians**Policy dataTreatment policies**•Medicaid coverage information•Formulary placement•Copays, prior authorization, etc.•RAND/NCSL•ASAMStrengths:+Can be linked to outcomes to examine effects of state policiesLimitations:-Collected through retrospective surveys, thus potentially inaccurate-Data is missing for some states**Contextual dataContextual factors**•Physician density•Hospital beds per capita•State or county economic factors•BEA[\*](#tblfn2){ref-type="table-fn"}•AHRF[\*](#tblfn2){ref-type="table-fn"}Strengths:+Can control for state or county factors related to healthcare access or treatment needLimitations:-Lags in data availability[^2]

Self-reported measures of opioid misuse or opioid use disorder symptoms come from national household surveys such as the National Survey on Drug Use and Health (NSDUH) and National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) ([@b0070], [@b0290], [@b0785], [@b0810], [@b0995], [@b1100]). The NSDUH's information on self-reported receipt of and need for opioid use disorder treatment has also informed research on treatment need and utilization trends ([@b0070], [@b0420], [@b0540], [@b0595], [@b0610], [@b1060], [@b1285]). Commercial and Medicaid claims data ([@b0115], [@b0395], [@b0750], [@b0970], [@b1170]), Veterans Health Administration data ([@b0090], [@b0390]), inpatient and emergency department databases ([@b0505], [@b1145]), and electronic health records ([@b0100], [@b0190], [@b0920]) are also used to estimate rates of potential opioid misuse or opioid use disorders. These data sources are also commonly used to examine person-level sociodemographic and clinical risk factors associated with development of opioid use disorder ([@b0070], [@b0090], [@b0115], [@b0290], [@b0395], [@b0390], [@b0785], [@b0810], [@b0970], [@b0995], [@b1100], [@b1170]).

Opioid use disorder treatment rates have often been studied using the National Survey of Substance Abuse Treatment Services Data (N-SSATS) and the Treatment Episodes Data Set (TEDS) ([@b0380], [@b0415], [@b0610], [@b0780], [@b1065]). Analyses of treatment trajectories, variation in buprenorphine utilization, quality of care and patient adherence to buprenorphine, as well as buprenorphine providers' patient censuses ([@b1135]), instead generally use commercial or Medicaid claims ([@b0065], [@b0490], [@b0755], [@b0830], [@b1070], [@b1120], [@b1135], [@b1160], [@b1165]).

Research describing national trends and geographic variation in treatment supply and capacity often uses SAMHSA's Buprenorphine Waiver Notification System ([@b0365], [@b1125], [@b1130]) or the DEA's Active Controlled Substances Act Registrants Database (ACSA) ([@b0025], [@b0670], [@b1025]) to examine the supply of buprenorphine waivered physicians, while studies assessing the capacity of opioid treatment programs or availability of various types of medication-assisted treatment use N-SSATS state- or county-level data ([@b0365], [@b0380], [@b0600], [@b0610], [@b1130]).

Studies of state Medicaid policies' effects on treatment access and utilization of methadone and buprenorphine commonly use policy information from the RAND/National Conference of State Legislatures (RAND/NCSL) Survey ([@b0150], [@b1125]) or the American Society of Addiction Medicine (ASAM) survey of Medicaid programs ([@b1005], [@b1065]), while research examining state- or county-level factors related to treatment supply or demand often use BEA or AHRF measures of the unemployment rate and income per capita ([@b0365], [@b0670], [@b1125]); and AHRF information on physician density, percent of adults uninsured, hospital beds per capita, and urbanicity ([@b0365], [@b1125], [@b1130]).

To examine state and community-level factors associated with treatment utilization or supply, studies often link policy and contextual data sources at the state or county level to outcome data on the location of buprenorphine waivered physicians or buprenorphine use ([@b0570], [@b0670], [@b1065], [@b1125], [@b1120]). Others link aggregate measures of treatment need with measures of treatment capacity to identify areas with treatment shortages ([@b0365], [@b0610]).

### 3.2.1. Common interview themes {#s0035}

Interviewees frequently noted that most existing data sources do not contain information on block grant funded treatment, thereby providing only a partial picture of treatment utilization, and limiting accurate identification of treatment shortage areas. Interviewees also observed that current analyses of treatment patterns (i.e., patient or provider trajectories) are commonly unable to track individuals across insurance coverage transitions. Interviewees stressed the need to better understand the effects of opioid use disorder treatment quality on outcomes, studies for which EHRs can complement claims data ([@b0180], [@b0445], [@b0515]). Finally, interviewees highlighted the need for further study of opioid use disorder treatment among justice-involved individuals ([@b0005], [@b0450], [@b0680]), likely requiring linked substance abuse treatment and arrest or incarceration databases.

3.3. Promoting use of overdose-reversing drugs {#s0040}
----------------------------------------------

Overdose-reversing drugs, such as naloxone, play a critical role in opioid overdose prevention ([@b0110], [@b0330], [@b1195]). In this section, we describe measures, data sources, and data linkages used to describe policies to promote naloxone distribution and use, and to evaluate how naloxone policies or programs relate to naloxone distribution, opioid overdose mortality, and contextual factors.

Information on state naloxone policies regarding use by community bystanders, emergency medical services (EMS) personnel, and other first responders is generally drawn from original reviews of legal databases ([@b0125], [@b0160], [@b0330], [@b0345]), with some groups, such as PDAPS, compiling data on the timing and provisions of certain laws into a single source ([Table 3](#t0015){ref-type="table"}).Table 3Secondary Data Sources to Support Research Promoting Use of Overdose-Reversing Drugs.**Data Elements (by Topic)SourcesStrengths and LimitationsPolicy dataNaloxone policies**•Good Samaritan laws•Naloxone access laws•PDAPS•NAMSDL[\*](#tblfn3){ref-type="table-fn"}•NCSL[\*](#tblfn3){ref-type="table-fn"}Strengths:+Can be linked with data on opioid outcomes to examine state policy impactLimitations:-May not capture state variation in nominally identical naloxone policies-Data on EMS protocols not readily available-Some data not provided in readily analyzable format**Mortality dataOpioid overdose mortality**•Opioid analgesic, heroin, or synthetic overdose deaths•Age, gender, race/ethnicity•State or county•CDC WONDER[\*](#tblfn3){ref-type="table-fn"}•NVSS MCODStrengths:+National data with information on opioid overdose mortality+CDC WONDER is readily downloadable and publicly availableLimitations:-Lags in data availability-Variation in quality of reporting detail on drug involvement due to differences across states in rigor of medical examiner/coroner procedures**EHR and claims dataNaloxone distribution**•Naloxone prescriptions•Prescriber specialty•Patient age and gender•Naloxone formulation**Pharmacy claims**•IQVIA•Symphony HealthStrengths:+Measures pharmacy distribution of naloxoneLimitations:-Only captures the distribution of naloxone via pharmacy channel; does not capture purchase and distribution via state or community programs**VHA data warehouse**Strengths:+Rich information on patient characteristics+Able to examine naloxone refills and renewalsLimitations:-Limited accessibility**Other national and local sourcesNaloxone distribution**•\# persons trained•\# naloxone kits provided•\# overdose reversals**OEND Program Data**•MA OOP Pilot Program•Harm Reduction CoalitionStrengths:+Fills in some gaps regarding naloxone distributed via state or local programsLimitations:-Data collection on OEND programs not standardized-National data not systematically collected, updated, or made publicly available**Other national sourcesNaloxone distribution**•EMS naloxone administration•EMS provider level•911 call info•Information on incident and transport**EMS data**•NEMSIS[\*](#tblfn3){ref-type="table-fn"}Strengths:+Naloxone administration is a fairly high-quality variable+Can do small area analysisLimitations:-Not a registry of patients receiving care-Data quality differs across agencies/states-Some elements restricted; contains no diagnosis information-Barriers to linking**Contextual dataContextual factors**•Other opioid-related policies•State or county-level demographics, socioeconomics•CPS[\*](#tblfn3){ref-type="table-fn"}•BLS[\*](#tblfn3){ref-type="table-fn"}•US Census[\*](#tblfn3){ref-type="table-fn"}•PDAPS•NAMSDL[\*](#tblfn3){ref-type="table-fn"}Strengths:+Can control for state or county factors associated with opioid mortalityLimitations:-Lags in data availability-Policy data often not available in readily analyzable format[^3]

Studies of community-based overdose education and naloxone distribution (OEND) programs ([@b0270], [@b0465], [@b0525], [@b0655], [@b0845]) commonly rely on surveys of OEND program participants, including reported overdose reversals, number of naloxone administrations, number of naloxone kits distributed, and overdose response, collected by OEND programs ([@b0085], [@b0370], [@b0400], [@b0620], [@b0870], [@b1225], [@b1230], [@b1270], [@b1275]). National data on the locations of OEND programs has been compiled by the Harm Reduction Council, but the data are not publicly available ([@b0705], [@b0710]). Fewer studies have examined retail pharmacy naloxone dispensing using pharmacy claims (e.g., Symphony Health, IQVIA) ([@b0435], [@b0615], [@b1290]) or EMS naloxone administration using National EMS Information System (NEMSIS) data to examine trends and geographic variation in naloxone distribution ([@b0195], [@b0405], [@b0410]). Another set of studies evaluated naloxone prescribing through the VHA OEND program ([@b0105], [@b0875]).

To examine how state naloxone policies or local OEND programs influence mortality, multi-state analyses generally use state-level data on opioid overdose mortality from the NVSS MCOD microdata or CDC WONDER ([@b0430], [@b0890], [@b0985], [@b1275]), while single-state analyses more commonly use state-or county-level measures collected from state death certificates ([@b0010], [@b0155], [@b0805], [@b1230]).

Studies of state naloxone policies' effects on opioid overdose generally merge state-level opioid overdose mortality data with information on state naloxone policies ([@b0890], [@b0985]); other community-level contextual factors, such as unemployment rates or per capita income from the CPS or US Census ([@b0890], [@b0985], [@b1230]); and information about other state opioid policies (e.g., pain clinic laws) from PDAPS, the Policy Surveillance Program, or NAMSDL ([@b0890], [@b0985]). Studies of the impact of OEND programs instead often use multiple complementary datasets, including parallel analyses of trends in emergency department visits, fatal accident poisonings, and outpatient-dispensed controlled substances ([@b0010], [@b1230]). Sub-county level studies using linked data are rare. One study linked police naloxone use to EMS data to assess the proportion of cases in which EMS administered additional naloxone doses ([@b0425]), while another single-county study mapped naloxone-carrying pharmacies with overdose death data at the ZIP Code level ([@b0155]).

### 3.3.1. Common interview themes {#s0045}

Interviewees frequently noted that more systematic collection of data on naloxone distribution outside of outpatient pharmacy channels would further understanding of naloxone access barriers and inform effective approaches for distribution and use. Interviewees also discussed how determining optimal naloxone dosing, particularly in the context of more widespread use of synthetic opioids ([@b0430]), would benefit from better data about naloxone reversals and the surrounding circumstances. Several interviewees noted the potential value of EMS data ([Table 3](#t0015){ref-type="table"}), but observed that variation in EMS data quality and completeness across agencies and regulatory barriers precluding individual level linkages currently limit its value, as analyses of EMS naloxone administration and subsequent patient outcomes are often confined to a single jurisdiction ([@b0080], [@b0665], [@b0735], [@b0975]). Many interviewees also noted the potential value of longitudinal studies linking data on persons receiving naloxone with claims data, which would enable researchers to follow individuals through the health care system.

3.4. Strengthening data for better public Health surveillance {#s0050}
-------------------------------------------------------------

The rapid evolution of opioid use and markets has generated efforts to improve data collection and surveillance tools to monitor medical and non-medical opioid use. In this section, we describe measures, data sources, and linkages used to study opioid surveillance topics not discussed extensively in the sections above, including detection of misuse, product-specific use and emerging trends, toxico-surveillance, and illicit markets ([Table 4](#t0020){ref-type="table"}), and we summarize common themes in this area from the interviews.Table 4Secondary Data Sources to Support Strengthening Data for Better Public Health Surveillance.**Data Elements (by Topic)SourcesStrengths and LimitationsPrescription drug monitoring dataDetection of opioid misuse**•Prescription name/type•Prescription dose•Prescriber•Payment•State PDMP•PBSSStrengths:+Comprehensive data on prescribing (i.e., multi-payer)+Can be used to develop measures around patient, prescriber, and pharmacist risky behaviorsLimitations:-Access barriers-State capacity issues may limit ability to link PDMP data with other datasets**Mortality dataOpioid-related overdose**•Cause of death•Drugs involved in death•Demographics•NDI•NVSS MCOD•CDC WONDER[\*](#tblfn4){ref-type="table-fn"}•State vital recordsStrengths:+National data with information on opioid overdose mortality+CDC WONDER is readily downloadable and publicly availableLimitations:-Lags in data availability-Variation in quality of reporting detail on drug involvement**Other national sourcesDetection of opioid misuse**•Inpatient stays and ED visits•Nonfatal overdose•Opioid use disorder•Diagnoses and procedures•**HCUP** (national and state inpatient and emergency department databases)Strengths:+Large collection of longitudinal data, nation-wide and state-level+State data is mapped to a standardized formatLimitations:-Not all states participate in the three state-level databases-Costs to obtain full datasets**Enhanced state opioid overdose surveillance**Strengths:+Very rich detail integrated from ED hospital billing, EMS, and syndromic surveillance data+Timely data availability and comparability across jurisdictionsLimitations:-Not currently available for all states**Toxico-surveillance**•Opioid-related poison center calls•Exposure type (e.g., intentional abuse exposures)**Poison Control**•NPDSStrengths:+Product and drug specific informationLimitations:-Must be requested and purchased-Lags in availability vary by poison center**Product-specific use & trends**•Opioid use/initiation•Route of administration**Toxico-surveillance**•Nonfatal opioid overdose**Illicit opioid markets**•Source of opioids**Proprietary surveillance**•RADARS•NAVIPPROStrengths:+Multifaceted data collection including product and drug specific information+Can identify exposure among high-risk groups (e.g., pregnant women)+RADARS has information on product street pricesLimitations:-Not nationally representative-Possible sampling biases-Costs to obtain**Toxico-surveillance**•Opioid-related ED visits•Substance with composition and formulation-specific differentiation**ED surveillance**•DAWN[\*](#tblfn4){ref-type="table-fn"}Strengths:+Nationally representative and generalizable+Mortality data available for a subset of statesLimitations:-Discontinued in 2011-Possible sampling and information biases**Illicit opioid markets**•Drug category; drug chemistry•Prevalence and location of emerging drugs•Street price (STRIDE)**Drug seizure or testing data**•NFLIS•STRIDEStrengths:+Data on illicit drug supply, prices, and purity+Seizure data often available with less lag time+Useful in constructing models of the likely course of the epidemicLimitations:-Access barriers (particularly for sub-state data)-Some drugs seizures are not analyzed by participating laboratories**Other state and local sourcesIllicit opioid markets**•Criminal history•Drug-related offenses and arrests•Demographics**Drug arrest data from state or local criminal justice agencies**Strengths:+Could be used to examine network patterns of co-arrests+If linked with other data, can assess systematic histories leading to arrestLimitations:-Often not available in electronic form that is usable-Difficulties in obtaining data use permissions**Detection of opioid misuse**•Opioid-related inpatient stays and ED visits•Diagnoses and procedures•Costs**HCUP** (State Inpatient and State Emergency Department Databases)Strengths:+Large collection of state-level longitudinal data+State data is mapped to a standardized formatLimitations:-Not all states participate-Costs to obtain full datasets**State inpatient, ED, mortality, or syndromic surveillance sources**Strengths:+Often available with less time lag than national sources+May be linkable to variety of state data sourcesLimitations:-Access and cost barriers vary across sources-State-specific so challenges for cross-state comparison**National surveysIllicit opioid markets**•Self-reported drug use•Urinalysis test results•Substance abuse treatment history•Drug acquisition and payment**Arrestee Survey**•ADAM[\*](#tblfn4){ref-type="table-fn"}Strengths:+Captures a high-risk population with uniform data collection across sitesLimitations:-Limited to few sites collecting data and male arrestees only-No longer fully operational-Certain data elements are restricted access[^4]

State PDMP data systems, now present to some degree in all 50 states, are increasingly being used to develop risk indicators for inappropriate prescriber behavior ([@b0695], [@b0935], [@b1015]) and to detect inappropriate or problematic patterns in opioid analgesic prescribing, dispensing, and use ([@b0645], [@b0860], [@b1175]). EHR data is also used to improve surveillance of problematic opioid use and opioid-related harms ([@b0880]), occasionally using natural language processing to text mine clinicians' notes ([@b0185], [@b0190]).

Proprietary databases, such as RADARS and NAVIPPRO, are also being used for near-real-time surveillance of opioid use. RADARS consists of several programs that collect and compile data on product-specific drug diversion and nonfatal overdose, opioid use and treatment, and street drug prices ([@b0060], [@b0170], [@b0200], [@b0220], [@b0255], [@b0300], [@b0310], [@b0340], [@b0575], [@b1100]). NAVIPPRO collects and compiles information on product-specific opioid use, initiation, route of administration, and source of opioids from two proprietary systems and several publicly available data sources ([@b0175], [@b0165], [@b0170], [@b0220], [@b0300], [@b1100]). Non-traditional data resources such as Twitter, web forum postings, Google trends, and cryptomarket forums on the Dark Web are also drawing attention as means to bolster public health surveillance, better understand opioid misuse and prescription drug diversion ([@b0020], [@b0230], [@b0640]), forecast state-level mortality or nonfatal overdose ([@b0900], [@b1305]), and assess emerging trends in new psychoactive substances ([@b1200]).

RADARS data on diversion has been used to examine illicit pharmaceutical opioid markets ([@b0300], [@b0310], [@b0575]), and NSDUH ([@b0575], [@b0605]) and NAVIPPRO ([@b0200]) includes information on self-reported sources of prescription opioids for nonmedical use. While national data on drug seizures, drug testing, and illicit drug prices that could be used to examine trends and geographic variation in illicit opioid markets exist in the National Forensic Laboratory Information System (NFLIS) or System to Retrieve Information from Drug Evidence (STRIDE) ([@b0850], [@b1100]), we identified few empirical analyses using these measures ([@b1030], [@b1125]), and found local or state law enforcement databases to be more common sources of drug seizures and arrest data ([@b0140], [@b0925], [@b0980]).

While mortality microdata help monitor drug overdose mortality and polysubstance involvement in fatal overdose ([@b0585], [@b0635]), concerns about its use for public health surveillance have been raised due to state variation in procedures used by medical examiners and coroners to record manner of death and specific drugs involved in overdoses ([@b0340], [@b0760], [@b1040], [@b1045], [@b1235]). Alternative data sources that have been used to examine trends, geographic "hot spots," and product-specific characteristics for opioid-related overdose include Drug Abuse Warning Network (DAWN) emergency department data ([@b0060], [@b1105]), opioid-related toxic exposures through RADARS or the National Poison Data System (NPDS) ([@b0060], [@b0300], [@b0295], [@b0340], [@b0835]), detailed and timely information on fatal and nonfatal overdose through the Enhanced State Opioid Overdose Surveillance (ESOOS)/State Unintentional Drug Overdose Reporting System (SUDORS) ([@b0800], [@b1110], [@b1205]), and information about opioid-related overdose from state hospital discharge databases ([@b0225]) or emergency department syndromic surveillance systems ([@b0010], [@b0305], [@b1155]). While containing less detailed information on specific products involved in overdose, the Healthcare Cost and Utilization Project (H-CUP) suite of inpatient and emergency department databases have also been used to assess temporal and geographic variation in nonfatal opioid-related overdose ([@b0505], [@b1055], [@b1145], [@b1190], [@b1185]).

Much of the effort toward bettering data for public health surveillance involves state strategies to facilitate linkages of multiple data sources ([@b0010], [@b0060], [@b0220], [@b0300], [@b0340], [@b0575]), across multiple state agencies. For example, with Chapter 55 of the Acts of 2015, Massachusetts' Department of Public Health developed a data warehouse providing person-level linkages across ten datasets managed by five state agencies, including the state all-payer claims database; state PDMP; death certificate records and toxicology results; substance abuse treatment information; hospital, emergency department, and outpatient records; criminal justice incarceration and treatment records; and emergency medical service data ([@b0795]). Maryland also is advancing efforts to link person-level data from the PDMP, drug use and alcohol treatment admissions, hospital admissions, fatalities, and criminal justice data ([@b0765], [@b1075]).

### 3.4.1. Common interview themes {#s0055}

Interviewees highlighted the need for surveillance efforts to consider the opioid crisis as a dynamic system with multiple agents and networks of interacting individuals and agencies ([@b0145], [@b1220]), involving both licit and illicit markets. Linking opioid prescribing or dispensing data with data about illicit opioid users and illicit drug markets, such as that available in the recently scaled back Arrestee Drug Abuse Monitoring System (ADAM; [Table 4](#t0020){ref-type="table"}), could be used to systematically examine individuals' histories associated with arrests, indicators of diversion, or movement between heroin and opioid analgesic markets. Interviewees also commonly discussed the need for more rapid data collection and analyses of other data sources, such as nonfatal overdose or drug seizure data, that can complement mortality data ([@b1040], [@b1235]) and allow timelier understanding of emerging trends and facilitate more appropriately tailored interventions ([@b0565]). Rhode Island's Opioid Overdose Reporting System ([@b0815]) and North Carolina's Disease Event Tracking and Epidemiologic Collection Tool are examples of state efforts toward near-real time collection and analysis of statewide nonfatal overdose data ([@b0580]). Many interviewees also mentioned other novel efforts to leverage novel data sources (e.g., social media, the Dark Web) combined with machine learning techniques to identify risks and emerging trends ([@b0130], [@b0625], [@b0630]), as well as the potential benefits of linking claims or PDMP data with social services data (e.g., child welfare data) to augment ecological analyses ([@b0460], [@b0885], [@b0945], [@b0955], [@b0950]) and better understand the consequences of opioid misuse and opioid use disorder treatment on child welfare outcomes.

4. Discussion {#s0060}
=============

Many efforts to inform strategies to combat the opioid crisis rely on analyses of secondary data. To further these efforts, this study is intended to enhance researcher awareness regarding the many existing data sources that can be used to address key HHS strategies, identify ways in which data sources can be used together to address questions more effectively than is possible with a single data source, and highlight existing data source strengths and limitations, innovative uses of data and data linkages, and opportunities to use such data to address high-priority research questions.

We identified a broad range of available data resources that researchers are using to examine a range of issues related to the opioid crisis, as well as many of the combinations of data sources being used by researchers to examine how the community and policy context relates to opioid-related outcomes. The value and availability of HHS support for data collection, aggregation and dissemination in addressing the opioid crisis is highlighted by the frequency with which researchers are using federal data sources, including surveys, claims data, policy data, and data from the census and other federal agencies. Such federal investments, and the consideration of future investments to enhance the quality and availability of data, such as linking mortality data to federal claims data, supporting the development of and access to all-payer claims databases, and encouraging the integration of criminal justice and public health datasets, are highlighted by our findings as critical steps to enhance the quality of future opioid-related research.

Our discussions with experts also emphasized a range of actions that do not require a substantial investment but appear likely to enhance the quality, availability, and usability of existing data. These include establishing standards for determining opioid-related cause of death, making overdose data available in a timelier manner, and ensuring available data is provided in formats that facilitate incorporation into analytic software. Even in the short time period since our interviews took place, some progress has been made to fill the identified gaps in research. Researchers have increasingly leveraged information from state APCDs -- linked or as a standalone data source -- to understand the intersection of patient conditions, opioid use, non-opioid therapies, and opioid-related harms; and to better estimate state-level population prevalence of opioid use disorder ([@b0050], [@b0055], [@b0720], [@b0775], [@b1265]). Recent funding for the Enhanced State Opioid Overdose Surveillance (ESOOS) system has allowed for the collection of more timely and comprehensive data on fatal overdoses from over 30 states; however, to our knowledge, these data have not yet been made widely available to researchers for use beyond in the creation of reports by state health departments and the CDC ([@b0480], [@b0800], [@b0855], [@b1080], [@b1205]). Making such data available to a broader array of researchers, and facilitating their linkage with other data sources, such as those with information on prescription drug use or criminal justice history, is one potential opportunity that could greatly enhance the value of these existing data sources.

5. Limitations {#s0065}
==============

There are a number of limitations of this work that merit discussion. There is a tremendous amount of research being done related to the opioid crisis, with new papers being published in high quality journals weekly. Furthermore, the scoping study should not be considered a structured systematic literature review, thus there are studies and data sources not captured in this document and many of the key questions identified are ones that we expect investigators are already examining. Furthermore, we recognize that categorizing data sources and research questions by HHS strategy is somewhat arbitrary, and that the most influential research often crosses these categories.

Finally, while this review has taken an expansive perspective to highlight the breadth of potential resources available to researchers studying opioid policy, a deeper dive into any one area may yield further insights and challenges. The opioid crisis is complex, and there is a need to better understand the expected time course of a given policy's effect, determine the role of heterogeneous policy implementation in differentially influencing outcomes, understand how the adoption of multiple policies may interact to enhance or diminish any given policy's impact, and determine how a variety of important outcomes may be impacted by policy even if not the intended target of the intervention. Existing ecological research has highlighted the need to monitor multiple datasets simultaneously, and further research that can leverage individual-level record linkages and longitudinal information on individual outcomes will enhance our understanding of ecological associations in order to guide more informed policy design.

5.1. Conclusions {#s0070}
----------------

Given the human and societal toll of the opioid crisis, efforts to create and make available improved data assets to support more informed efforts to address the opioid crisis are a public health imperative. Overall, there are a variety of areas in which resources and time may be invested to enhance use and linkage of existing secondary data sources for opioid research. A tremendous amount of work is being done at the federal, state, and local levels to combat the opioids crisis. There has also been a substantial increase in research that has improved our understanding of the complex and multi-dimensional nature of the opioid crisis, as well as advanced the evidence base regarding the effectiveness of opioid policies and initiatives toward reducing opioid-related harms. While significant resources for the use and analysis of secondary data exist, not all are being optimized. This work serves to enhance awareness of existing data resources relevant to opioid research, describe the scope of research leveraging these datasets, and highlight some key research gaps, data limitations, and data linkage needs that future research can address to further efforts to combat the opioids crisis.
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